Expert Opinion on Pharmacotherapy

Papers
(The H4-Index of Expert Opinion on Pharmacotherapy is 21. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-06-01 to 2026-06-01.)
ArticleCitations
Oral anticoagulation therapy in the setting of liver disease69
An overview of mineralocorticoid receptor antagonists as a treatment option for patients with heart failure: the current state-of-the-art and future outlook50
Promising therapies for adults with symptomatic obstructive hypertrophic cardiomyopathy: 2023 and beyond48
Rheumatoid arthritis in Latin America: pharmacotherapy and clinical challenges44
Current treatment options for Mycobacterium marinum cutaneous infections41
A 2023 update on the advancements in the treatment of agitation in Alzheimer’s disease38
Evaluating the safety and efficacy of seladelpar for adults with primary biliary cholangitis38
The pharmacological treatment and management of hyperhidrosis35
Real-world safety and effectiveness of roxadustat in patients with anemia of chronic kidney disease: interim results from a post-marketing surveillance study in Japan31
Pharmacotherapy developments in autophagy inhibitors for bladder cancer29
Efficacy of 3-day versus 5-day aprepitant regimens for long-delayed chemotherapy-induced nausea and vomiting in patients receiving cisplatin-based chemotherapy28
Antidepressant medications in women aged 40 and older and the risk of fragility fractures: a systematic literature review and meta-analysis27
GnRH agonists and antagonists in therapy of symptomatic uterine fibroids – current roles and future perspectives26
Thrombopoietin receptor agonists in immune thrombocytopenia: a comparative review of mechanisms, efficacy, and the future of personalized management26
How have gamma-secretase inhibitors changed the treatment landscape for desmoid tumors?26
Advances in the management of obstructive hypertrophic cardiomyopathy: The role of mavacamten25
Pivmecillinam: past, present, and future24
Perspectives on the advances in the pharmacotherapeutic management of Duchenne muscular dystrophy24
An evaluation of ivosidenib for the treatment of IDH1-mutant cholangiocarcinoma23
Current and emerging pharmacotherapies for the treatment of pulmonary arterial hypertension in infants23
Expanding indications and developmental landscape of HER2-targeted therapies in breast cancer: a pharmacotherapeutic perspective21
Selecting optimal therapy in systemic mastocytosis: current state and future directions21
Pharmacologic management of ET: established therapies and emerging agents21
When is pharmacotherapy necessary for the treatment of seasonal affective disorder?21
0.11593890190125